Yamin Liu

Southeast University China

Yamin Liu is a clinical pharmacist and assistant professor in Zhongda hospital, Southeast University, China. She received her PhD in Clinical Pharmacy from China Pharmaceutical University. She also has been a visiting scholar in Cardiology Department, Johns Hopkins University. She has published 26 papers in local and international peer-reviewed journals in the field of pharmacy, cardiology and genomics. She is a member of the American Heart Association and Clinical Pharmacy Association of Jiangsu China. In addition, she had been awarded and completed several grants from the Jiangsu Pharmaceutical Association.

1books edited

1chapters authored

Latest work with IntechOpen by Yamin Liu

Polymorphism or variation in DNA sequence can affect individual phenotypes such as color of skin or eyes, susceptibility to diseases, and response to drugs, vaccines, chemicals, and pathogens. Especially, the interfaces between genetics, disease susceptibility, and pharmacogenomics have recently been the subject of intense research activity. This book is a self-contained collection of valuable scholarly papers related to genetic diversity and disease susceptibility, pharmacogenomics, ongoing advances in technology, and analytic methods in this field. The book contains nine chapters that cover the three main topics of genetic polymorphism, genetic diversity, and disease susceptibility and pharmacogenomics. Hence, this book is particularly useful to academics, scientists, physicians, pharmacists, practicing researchers, and postgraduate students whose work relates to genetic polymorphisms.

Go to the book

Genetic Diversity and Disease Susceptibility

Edited by Yamin Liu

Chapters authored

Recent Advances in Hypertrophic Cardiomyopathy: A System Review

By Yamin Liu, Zhao Li, Xiaofan Guo, Xiong Jing, Xueli Zhang, Hua Shao, Yufan Guan and Maria R. Abraham

Hypertrophic cardiomyopathy (HCM) is a common genetic cardiovascular disease present in 1 in 500 of the general population, leading to the most frequent cause of sudden death in young people (including trained athletes), heart failure, and stroke. HCM is an autosomal dominant inheritance, which is associated with a large number of mutations in genes encoding proteins of the cardiac sarcomere. Over the last 20 years, the recognition, diagnosis, and treatment of HCM have been improved dramatically. And moreover, recent advancement in genomic medicine, the growing amount of data from genotype-phenotype correlation studies, and new pathways for HCM help the progress in understanding the diagnosis, mechanism, and treatment of HCM. In this chapter, we aim to outline the symptoms, complications, and diagnosis of HCM; update pathogenic variants (including miRNAs); review the treatment of HCM; and discuss current treatment and efforts to study HCM using induced pluripotent stem cell–derived cardiomyocytes and gene editing technologies. The authors ultimately hope that this chapter will stimulate further research, drive novel discoveries, and contribute to the precision medicine in diagnosis and therapy for HCM.

Part of the book: Genetic Polymorphisms

Yamin Liu

Latest work with IntechOpen by Yamin Liu

Genetic Diversity and Disease Susceptibility

Chapters authored

Related collaborators

Francesco Fedele

Igor A. Sobenin

Beata Kaleta

Yasemin Başbınar

Seniz Demiryürek

Abdullah Tuncay Demiryürek

Urszula Kaczor

Gizem Calibasi Kocal

Paolo Severino

Mariateresa Pucci